Instil Bio to Present at Morgan Stanley Global Healthcare Conference
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (TIL" href="/company/TIL" onmouseover="handlePagePreview('company','TIL')" style="color:#4007a2 !important; text-decoration:underline !important; font-weight:bold;">Nasdaq: TILTIL-pp">), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference:
Morgan Stanley 20th Annual Global Healthcare Conference
Fireside Chat: Monday, September 12, 2022 at 2:50 p.m. ET
A live webcast, if recorded, of each presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Company’s website shortly after the event.
About Instil Bio
Instil Bio, Inc. (TIL" href="/company/TIL" onmouseover="handlePagePreview('company','TIL')" style="color:#4007a2 !important; text-decoration:underline !important; font-weight:bold;">Nasdaq: TILTIL-pp">) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.
Contacts:
Investor Relations
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
Janhavi Mohite
Stern Investor Relations
1-212-362-1200
janhavi.mohite@sternir.com
